Replimune REPL Insider Ownership

Updated Oct 5, 2026

Over the past year, REPL insiders sold $1.93 million of stock (216.59K shares) on the open market and bought none.

• A count shows 7 insiders selling REPL stock on the open market over the past 12 months and none buying.
• Sushil Patel (Chief Executive Officer) was REPL's largest open-market seller in the past 12 months, with $811,159 of sales (86.67K shares); the latest was on August 10, 2026.
• The latest open-market trade on record is a sale of 9.26K shares for $132,176 by Emily Luisa Hill (Chief Financial Officer) on August 17, 2026.
• In transactions other than open-market trades, Replimune insiders received 606.24K shares in stock awards, acquired 3.17K shares through option exercises and conversions and gave away 75K shares as gifts over the past 12 months.
• Business Quant data shows Replimune insiders holding 2.79Mn shares in total in their latest Form 4 filings, or 2.88% of the 96.86Mn shares outstanding; that total is down 4.42% from 2.92Mn shares at the end of Q2 2026.
• All of the 2.79Mn shares held by Replimune insiders are held directly, none through trusts, partnerships or other entities.
• The insider holdings in Replimune belong to 6 insiders who have reported on Form 4 within the past two years.
• REPL's largest insider holders by reported holdings are Philip Astley-Sparke (Director, 1.36Mn shares), Sushil Patel (Chief Executive Officer, 708.15K shares) and Konstantinos Xynos (Chief Medical Officer, 224.22K shares).
• The holding of Philip Astley-Sparke makes up 48.81% of all shares held by Replimune insiders.
• Over the past 12 months, 14 insiders reported transactions in Replimune stock in 39 Form 4 filings.
• Insider figures for REPL include Form 4 filings through August 24, 2026.